Has varicella vaccination been as cost-effective as anticipated when
it was universally recommended for children 10 years ago? The answer is complicated
and illuminates an evolving controversy regarding the role of cost-effectiveness
analyses in deliberations over national vaccine recommendations.
In 1994, Lieu and colleagues1 estimated
the cost-effectiveness of a universal childhood varicella vaccination program.
Projecting a national vaccination rate of 97% by the sixth year of the program,
they estimated a 94% reduction in varicella incidence, accompanied by an 89%
reduction in direct medical costs. Accounting as well for reductions in the
quantity of parents’ and other adults’ lost work time attributable
to varicella (ie, the “indirect” benefits of vaccination), Lieu
et al projected that a varicella vaccination program would save more than
$5 for every $1 spent.1
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 9
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.